Chronic Myelogenous Leukemia Treatment Market - 2024-2031
The Chronic Myelogenous Leukemia Treatment Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Chronic Myelogenous Leukemia Treatment Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Type
Both primary and secondary data sources have been used in the global Chronic Myelogenous Leukemia Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
A Chronic Myelogenous Leukemia Treatment Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Type
- Bosulif (Bosutinib)*
- Gleevec (Imatinib)
- Iclusig (Ponatinib)
- Sprycel (Dasatinib)
- Tasigna (Nilotinib)
- Synribo (Omacetaxine Mepesuccinate)
- Asciminib
- Others
- Targeted therapy*
- Chemotherapy
- Biologic therapy
- Others
- Hospitals *
- Clinics
- Ambulatory Surgical Centers
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Chronic Myelogenous Leukemia Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Treatment Type
3.2. Market Snippet by Drug Type
3.3. Market Snippet by End User
3.4. Market Snippet by Region
4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA TREATMENT MARKET – MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of chronic myelogenous leukaemia (CML) will drive the market growth
4.1.1.2. The presence of a robust domain for cancer treatment will drive market growth
4.1.2. Restraints:
4.1.2.1. Complications related to chemotherapy and stringent regulations on drugs will hamper the market
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Epidemiology Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Reimbursement Analysis
5.7. Unmet Needs
6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA TREATMENT MARKET – COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
7.1.2. Market Attractiveness Index, By Surgical Devices Segment
7.2. Bosulif (Bosutinib)*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Gleevec (Imatinib)
7.4. Iclusig (Ponatinib)
7.5. Sprycel (Dasatinib)
7.6. Tasigna (Nilotinib)
7.7. Synribo (Omacetaxine Mepesuccinate)
7.8. Asciminib
7.9. Others
8. BY TREATMENT TYPE
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Targeted therapy*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Chemotherapy
8.4. Biologic therapy
8.5. Others
9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA TREATMENT MARKET – BY END USER
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
9.1.2. Market Attractiveness Index, By End User Segment
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Clinics
9.4. Ambulatory Surgical Centers
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Types
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. Key Companies to Watch
11.5. Company with disruptive technology
11.6. Start Up Companies
12. COMPANY PROFILES
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Bristol-Myers Squibb
12.3. Teva Pharmaceuticals Industries Ltd.
12.4. ARIAD Pharmaceuticals, Inc.
12.5. Pfizer, Inc.
12.6. Hospira, Inc.
12.7. CStone Pharma
12.8. JD Health
12.9. Jiangsu Hengrui Medicine Co., Ltd
12.10. Shanghai Junshi Biosciences Co., Ltd.(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Treatment Type
3.2. Market Snippet by Drug Type
3.3. Market Snippet by End User
3.4. Market Snippet by Region
4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA TREATMENT MARKET – MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of chronic myelogenous leukaemia (CML) will drive the market growth
4.1.1.2. The presence of a robust domain for cancer treatment will drive market growth
4.1.2. Restraints:
4.1.2.1. Complications related to chemotherapy and stringent regulations on drugs will hamper the market
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Epidemiology Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Reimbursement Analysis
5.7. Unmet Needs
6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA TREATMENT MARKET – COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
7.1.2. Market Attractiveness Index, By Surgical Devices Segment
7.2. Bosulif (Bosutinib)*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Gleevec (Imatinib)
7.4. Iclusig (Ponatinib)
7.5. Sprycel (Dasatinib)
7.6. Tasigna (Nilotinib)
7.7. Synribo (Omacetaxine Mepesuccinate)
7.8. Asciminib
7.9. Others
8. BY TREATMENT TYPE
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Targeted therapy*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Chemotherapy
8.4. Biologic therapy
8.5. Others
9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA TREATMENT MARKET – BY END USER
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
9.1.2. Market Attractiveness Index, By End User Segment
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Clinics
9.4. Ambulatory Surgical Centers
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Types
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. Key Companies to Watch
11.5. Company with disruptive technology
11.6. Start Up Companies
12. COMPANY PROFILES
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Bristol-Myers Squibb
12.3. Teva Pharmaceuticals Industries Ltd.
12.4. ARIAD Pharmaceuticals, Inc.
12.5. Pfizer, Inc.
12.6. Hospira, Inc.
12.7. CStone Pharma
12.8. JD Health
12.9. Jiangsu Hengrui Medicine Co., Ltd
12.10. Shanghai Junshi Biosciences Co., Ltd.(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us
